Intellia Therapeutics (38I) Ownership - Who Owns Intellia Therapeutics?
Intellia Therapeutics (38I) Ownership Overview
- 1.84% Insiders
- 19.34% Mutual Funds
- 3.78% Other Institutional Investors
- 31.98% ETFs
- 43.06% Public Companies and Individual Investors
The ownership structure of Intellia Therapeutics (DE:38I) stock is a mix of institutional, retail, and individual investors. Approximately 55.10% of the company’s stock is owned by Institutional Investors, 1.84% is owned by Insiders, and 43.06% is owned by Public Companies and Individual Investors.
The ownership structure of Intellia Therapeutics (DE:38I) stock is a mix of institutional, retail, and individual investors. Approximately 55.10% of the company’s stock is owned by Institutional Investors, 1.84% is owned by Insiders, and 43.06% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Jul 23, 2026 | Edward J Iii Dulac | $91,249 | |
| Jul 05, 2026 | Michael P Dube | $44,316 | |
| Mar 02, 2026 | Eliana Clark | $8,364 | |
| Jan 06, 2026 | John M. Leonard | $314,485 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Graham Capital Management, L.p. | €263,820 | |
| Dec 31, 2025 | Bridgewater Associates, Lp | €2,006,262 | |
| Dec 31, 2025 | Ark Investment Management Llc | €127,723,842 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Cathie Wood | 16,875,684 | Institution | 12.04% | 210,271,023 |
| Ark | 15,336,327 | Institution | 10.94% | 191,090,634 |
| Vanguard | 12,140,145 | Institution | 8.66% | 151,266,207 |
| Vanguard Index Funds | 10,795,618 | Institution | 7.70% | 134,513,400 |
| Ishares | 6,672,020 | Institution | 4.76% | 83,133,369 |
| Spdr | 5,218,935 | Institution | 3.72% | 65,027,930 |
| Peter Kolchinsky | 4,526,926 | Institution | 3.23% | 56,405,498 |
| Fidelity Select Portfolios | 3,080,133 | Institution | 2.20% | 38,378,457 |
| Fidelity Salem Street Trust | 1,688,868 | Institution | 1.21% | 21,043,295 |
| Dfa | 1,543,697 | Institution | 1.10% | 19,234,465 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 10,795,618 | Institution | 7.70% | 134,513,400 |
| Fidelity Select Portfolios | 3,080,133 | Institution | 2.20% | 38,378,457 |
| Fidelity Salem Street Trust | 1,688,868 | Institution | 1.21% | 21,043,295 |
| Blackrock Funds | 1,309,189 | Institution | 0.93% | 16,312,495 |
| Fidelity Concord Street Trust | 1,292,058 | Institution | 0.92% | 16,099,043 |
| Dfa Investment Dimensions Group Inc | 1,281,309 | Institution | 0.91% | 15,965,110 |
| Vanguard Horizon Funds | 1,027,324 | Institution | 0.73% | 12,800,457 |
| Vanguard Scottsdale Funds | 888,693 | Institution | 0.63% | 11,073,115 |
| Federated Hermes Mdt Series | 820,243 | Institution | 0.59% | 10,220,228 |
| Fidelity Rutland Square Trust Ii | 707,056 | Institution | 0.50% | 8,809,918 |
FAQ
Who Owns Intellia Therapeutics (DE:38I)?
According to the latest TipRanks data, approximately 55.10% of the company's stock is held by institutional investors, 1.84% is held by insiders, and 43.06% is held by public companies and individual investors.
What percentage of Intellia Therapeutics (DE:38I) stock is held by institutional investors?
According to the latest TipRanks data, approximately 55.10% of Intellia Therapeutics (DE:38I) stock is held by institutional investors: 19.34% by mutual funds, 31.98% by ETFs and 3.78% by other institutional investors.
What percentage of Intellia Therapeutics (DE:38I) stock is held by retail investors?
According to the latest TipRanks data, approximately 43.06% of Intellia Therapeutics (DE:38I) stock is held by public companies and individual investors.
Who owns the most shares of Intellia Therapeutics (DE:38I)?
Cathie Wood owns the most shares of Intellia Therapeutics (DE:38I).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.